Ameloblastoma RNA profiling uncovers a distinct non-coding RNA signature
2017 (English)In: OncoTarget, ISSN 1949-2553, E-ISSN 1949-2553, Vol. 8, no 3, 4530-4542 p.Article in journal (Refereed) Published
Ameloblastoma of the jaws remains the top difficult to treat odontogenic tumour and has a high recurrence rate. New evidence suggests that non-coding RNAs (ncRNAs) play a critical role in tumourgenesis and prognosis of cancer. However, ameloblastoma ncRNA expression data is lacking. Here we present the first report of ameloblastoma ncRNA signatures. A total of 95 ameloblastoma cases and a global array transcriptome technology covering > 285.000 full-length transcripts were used in this two-step analysis. The analysis first identified in a test cohort 31 upregulated ameloblastoma-associated ncRNAs accompanied by signalling pathways of cancer, spliceosome, mRNA surveillance and Wnt. Further validation in an independent cohort points out the long non-coding (lncRNAs) and small nucleolar RNA (snoRNAs): LINC340, SNORD116-25, SNORA11, SNORA21, SNORA47 and SNORA65 as a distinct ncRNA signature of ameloblastoma. Importantly, the presence of these ncRNAs was independent of BRAFV600E and SMO-L412F mutations, histology type or tumour location, but was positively correlated with the tumour size. Taken together, this study shows a systematic investigation of ncRNA expression of ameloblastoma, and illuminates new diagnostic and therapeutic targets for this invasive odontogenic tumour.
Place, publisher, year, edition, pages
2017. Vol. 8, no 3, 4530-4542 p.
ameloblastoma, biomarkers, transcriptome, ncRNA, gene expression analysis
Cancer and Oncology Cell and Molecular Biology
IdentifiersURN: urn:nbn:se:uu:diva-317696DOI: 10.18632/oncotarget.13891ISI: 000393228400064PubMedID: 27965463OAI: oai:DiVA.org:uu-317696DiVA: diva2:1082665
FunderSwedish Cancer Society